Genetic architecture of FTLD-TDP pathological subtypes
Oriol Dols-Icardo1, Lianne M Reus2, Alfredo Ramirez3
1Sant Pau Memory Unit, IR SANT PAU, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
Trends in Neurosciences
|July 3, 2025
Summary
Researchers identified genetic risk factors for frontotemporal lobar degeneration with TDP-43 aggregation (FTLD-TDP) subtypes. This study enhances understanding of FTLD-TDP heterogeneity and underlying mechanisms.
Area of Science:
- Neurogenetics
- Neurodegenerative Diseases
- Molecular Biology
Background:
- Frontotemporal lobar degeneration with TDP-43 aggregation (FTLD-TDP) is a major cause of dementia.
- Genetic underpinnings of FTLD-TDP subtypes remain largely unknown.
- Identifying genetic factors is crucial for understanding disease mechanisms.
Purpose of the Study:
- To identify common and rare genetic variants associated with distinct FTLD-TDP subtypes.
- To provide novel insights into the genetic architecture of FTLD-TDP.
- To explore the heterogeneity of FTLD-TDP based on genetic factors.
Main Methods:
- Genome-wide association studies (GWAS) were employed.
- Analysis included both common and rare genetic variants.
- Statistical methods were used to associate variants with FTLD-TDP subtypes.
Main Results:
- Common and rare genetic variants linked to specific FTLD-TDP subtypes were identified.
- Novel genetic associations contributing to FTLD-TDP heterogeneity were discovered.
- The findings shed light on the molecular pathways involved in FTLD-TDP.
Conclusions:
- Genetic factors play a significant role in the distinct subtypes of FTLD-TDP.
- The identified variants offer new targets for research into FTLD-TDP.
- Understanding genetic heterogeneity is key to developing targeted therapies for FTLD-TDP.
Related Concept Videos
01:43Sex Linked Disorders
Like autosomes, sex chromosomes contain a variety of genes necessary for normal body function. When a mutation in one of these genes results in biological deficits, the disorder is considered sex-linked.
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:21Huntington Disease l: Introduction
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...